1. Home
  2. IMNM vs VCEL Comparison

IMNM vs VCEL Comparison

Compare IMNM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.12

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$46.67

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
VCEL
Founded
2006
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
IMNM
VCEL
Price
$22.12
$46.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$32.80
$57.75
AVG Volume (30 Days)
1.7M
704.3K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
60.00
EPS
N/A
N/A
Revenue
$6,941,000.00
$276,259,000.00
Revenue This Year
N/A
$19.40
Revenue Next Year
$1,127.34
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.45
52 Week Low
$8.67
$28.95
52 Week High
$27.65
$48.75

Technical Indicators

Market Signals
Indicator
IMNM
VCEL
Relative Strength Index (RSI) 52.69 62.32
Support Level $19.28 $32.47
Resistance Level $23.25 N/A
Average True Range (ATR) 1.36 1.77
MACD -0.03 -0.21
Stochastic Oscillator 45.98 60.54

Price Performance

Historical Comparison
IMNM
VCEL

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: